Platelet-leukocyte aggregates during hemodialysis: effect of membrane type
- PMID: 9950176
- DOI: 10.1046/j.1525-1594.1999.06289.x
Platelet-leukocyte aggregates during hemodialysis: effect of membrane type
Abstract
Hemodialysis is associated with the formation of platelet-leukocyte aggregates. Whether this phenomenon is hemodialysis (HD) membrane dependent is unclear. To evaluate this process, we examined respectively platelet activation (anti-CD41, anti-CD62, and antifibrinogen monoclonal antibodies [MoAb] binding), leukocyte activation (CD11b expression), and the appearance of platelet specific antigens on leukocytes as an index of platelet-leukocyte aggregation during HD using 3 different membrane materials, Cuprophan, Hemophan, and polysulfone. Flow cytometric techniques and specific MoAb were used. All parameters were assayed 5 min after initiation of HD to avoid the confounding variable of leukopenia and resultant cell subpopulation analysis. Platelet activation (anti-CD62 and antifibrinogen binding) occurred only with Cuprophan. All 3 membranes induced equivalent increases in CD11b expression on neutrophils and similarly increased the binding of anti-CD41 to neutrophils, reflecting an increment in the formation of platelet neutrophil aggregates. However, only Cuprophan induced an increase in anti-CD62 binding to neutrophils, suggesting that the aggregated platelets linked to neutrophils were activated. Increased anti-CD41 binding by monocytes was similarly observed with all 3 membranes. However, only polysulfone induced an increase in CD11b expression and fibrinogen binding to monocytes. We conclude that while the formation of platelet leukocyte aggregates appears to be a universal phenomenon in HD occurring with a variety of membrane types, subtypes of this phenomenon consisting of activated platelets and fibrinogen binding may be membrane dependent. This phenomenon may serve as a new biocompatibility parameter and may shed light on some of the biologic consequences of hemodialysis.
Similar articles
-
A new hydrophilic polysulfone hemodialysis membrane can prevent platelet-neutrophil interactions and successive neutrophil activation.Int J Artif Organs. 2019 Apr;42(4):175-181. doi: 10.1177/0391398818823767. Epub 2019 Jan 14. Int J Artif Organs. 2019. PMID: 30638104 Free PMC article.
-
Platelet-leukocyte aggregation during hemodialysis.Kidney Int. 1994 Aug;46(2):489-95. doi: 10.1038/ki.1994.299. Kidney Int. 1994. PMID: 7526025 Clinical Trial.
-
Platelet GPIIb/IIIa is activated and platelet-leukocyte coaggregates formed in vivo during hemodialysis.Nephron. 2002 Apr;90(4):391-400. doi: 10.1159/000054726. Nephron. 2002. PMID: 11961397
-
Interactions between platelets and leukocytes during hemodialysis.Artif Organs. 1999 Jan;23(1):23-8. doi: 10.1046/j.1525-1594.1999.06271.x. Artif Organs. 1999. PMID: 9950175 Review.
-
Amplification of the inflammatory response: adhesion molecules associated with platelet/white cell responses.J Cardiovasc Pharmacol. 1996;27 Suppl 1:S6-12. doi: 10.1097/00005344-199600001-00005. J Cardiovasc Pharmacol. 1996. PMID: 8938278 Review.
Cited by
-
A new hydrophilic polysulfone hemodialysis membrane can prevent platelet-neutrophil interactions and successive neutrophil activation.Int J Artif Organs. 2019 Apr;42(4):175-181. doi: 10.1177/0391398818823767. Epub 2019 Jan 14. Int J Artif Organs. 2019. PMID: 30638104 Free PMC article.
-
Diminished adhesion and activation of platelets and neutrophils with CD47 functionalized blood contacting surfaces.Biomaterials. 2012 Aug;33(24):5803-11. doi: 10.1016/j.biomaterials.2012.04.051. Epub 2012 May 20. Biomaterials. 2012. PMID: 22613135 Free PMC article.
-
Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study.Crit Care. 2008;12(4):R111. doi: 10.1186/cc6998. Epub 2008 Aug 29. Crit Care. 2008. PMID: 18759963 Free PMC article. Clinical Trial.
-
2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 1- Defining populations at risk.J Vet Emerg Crit Care (San Antonio). 2022 May;32(3):289-314. doi: 10.1111/vec.13204. Epub 2022 May 2. J Vet Emerg Crit Care (San Antonio). 2022. PMID: 35499966 Free PMC article.
-
Dealing with prognostic signature instability: a strategy illustrated for cardiovascular events in patients with end-stage renal disease.BMC Med Genomics. 2016 Jul 20;9(1):43. doi: 10.1186/s12920-016-0210-9. BMC Med Genomics. 2016. PMID: 27439789 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials